Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation

Transplantation
Y TomitaM Sykes

Abstract

While allogeneic bone marrow transplantation (BMT) has long been known to be capable of inducing donor-specific tolerance and hence permitting allograft acceptance without immunosuppressive pharmacotherapy, the toxicity of conditioning regimens required to achieve marrow engraftment has precluded the application of this approach to clinical organ transplantation. A relatively nontoxic method of conditioning mice that allows allogeneic bone marrow engraftment and induction of donor-specific skin allograft tolerance has recently been described. This regimen included anti-CD4 and anti-CD8 mAbs administered on day -5, followed by 3-Gy whole body irradiation (WBI) and 7-Gy thymic irradiation (TI) on day 0. To further reduce the potential toxicity of this regimen, we have now attempted to overcome the requirement for TI by administering additional mAb injections before and after BMT. Mixed chimerism and prolonged donor-specific skin graft acceptance were induced in 90% of B10 mice conditioned with anti-CD4 and -CD8 mAbs on days -6 and -1 and 3-Gy WBI on day 0 without TI. Despite long-term acceptance of donor-specific skin grafts, however, some of these animals showed a gradual decline in donor-type hematopoietic repopulation, and 2 o...Continue Reading

References

Mar 1, 1991·The Journal of Experimental Medicine·M InabaS Ikehara
Jan 1, 1988·Immunology Today·M Sykes, D H Sachs
Oct 3, 1953·Nature·R E BILLINGHAMP B MEDAWAR
Jan 1, 1987·Immunology Today·S Slavin

❮ Previous
Next ❯

Citations

Jan 1, 1997·Immunologic Research·B Nikolic, M Sykes
Sep 12, 2007·Cell and Tissue Research·Karl-Henrik GrinnemoMatthias Corbascio
Mar 27, 2001·Transplantation Proceedings·A P Monaco
Sep 25, 2002·Transplantation Proceedings·A P Monaco
Mar 15, 2000·Transplantation Proceedings·G L XiaM Waer
Nov 22, 1997·Current Opinion in Immunology·B Nikolic, M Sykes
Nov 5, 1999·Nature Medicine·H Waldmann
Sep 3, 2010·Nature Reviews. Nephrology·Nina Pilat, Thomas Wekerle
Jul 21, 1998·Annals of the New York Academy of Sciences·R StorbM C Walters
May 23, 1998·Annual Review of Immunology·H Waldmann, S Cobbold
Jan 22, 2000·The Journal of Clinical Investigation·C A HuangD H Sachs
Jun 23, 2000·The Journal of Clinical Investigation·Y FuchimotoD H Sachs
Dec 29, 1998·Transplantation Proceedings·M SykesY G Yang
Aug 16, 2002·Transplant Immunology·Thomas WekerleFerdinand Muehlbacher
Aug 16, 2011·Seminars in Immunology·David H SachsA Benedict Cosimi
Jan 20, 2009·International Immunopharmacology·Eran Ophir, Yair Reisner
Dec 18, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Yasuo TakeuchiMegan Sykes
Nov 18, 2003·Immunological Reviews·Xin Xiao ZhengTerry B Strom
Nov 18, 2003·Immunological Reviews·Andrew B AdamsChristian P Larsen
Jun 20, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Josef KurtzMegan Sykes
Aug 16, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Zhong GuoKenneth A Newell
Oct 3, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Z KoporcT Wekerle
Feb 12, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·K MinamimuraT Maki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.